Vous avez cherché: gastroenteritisa (Croate - Anglais)

može doći i do disfunkcije jetre i gastroenteritisa.
liver dysfunction and gastroenteritis may also occur.

to pomaže u sprečavanju gastroenteritisa uzrokovanog rotavirusom.
this helps to protect against gastroenteritis caused by rotavirus.

ova protutijela štite od gastroenteritisa uzrokovanog ovim tipovima rotavirusa.
these antibodies help protect against gastroenteritis caused by these types of rotavirus.

težina gastroenteritisa (ge) definirana je prema kriterijima szo.
severity of gastro-enteritis (ge) was defined according to who criteria.

hospitalizacija i dolazak na odjel hitne medicine zbog gastroenteritisa svih uzroka
hospitalization and ed visits due to all cause gastroenteritis

bilo koji oblik rotavirusnog gastroenteritisa rotarix n=2974 placebo n=1443
any rotavirus gastro-enteritis rotarix n=2,974 placebo n=1,443

imunološki mehanizam kojim rotarix štiti protiv rotavirusnog gastroenteritisa nije u potpunosti razjašnjen.
the immunologic mechanism by which rotarix protects against rotavirus gastro-enteritis is not completely understood.

djelotvornost cjepiva (%) protiv teškog oblika rotavirusnog gastroenteritisa (95% ci)
vaccine efficacy (%) against severe rotavirus gastro-enteritis (95% ci)

incidencija teških rv gastroenteritisa povezanih s pojedinim genotipovima je bila premala da bi dozvoljavala izračun djelotvornosti.
the incidence of severe rv gastro-enteritis associated with the individual genotypes was too small to allow calculation of efficacy.

rijetke nuspojave tijekom kliničkih ispitivanja obuhvaćale su anksioznost, periorbitalni edem, pospanost i znakove gastroenteritisa.
uncommon adverse reactions in clinical trials were anxiety, periorbital oedema, drowsiness and signs of gastroenteritis.

na temelju dokaza prikupljenih u kliničkim ispitivanjima, dojenje ne smanjuje zaštitu protiv rotavirusnog gastroenteritisa koju pruža rotarix.
based on evidence generated in clinical trials, breast-feeding does not reduce the protection against rotavirus gastro-enteritis afforded by rotarix.

broj slučajeva gastroenteritisa uzrokovanog rotavirusom zbog virusa s istim antigenima kao i u cjepivu smanjio se nakon cijepljenja lijekom rotateq.
the number of cases of rotavirus gastroenteritis due to viruses with the same antigens as in the vaccine decreased following vaccination with rotateq.

klinička ispitivanja djelotvornosti cjepiva protiv gastroenteritisa uzrokovanog rotavirusom provedena su u europi, sjedinjenim američkim državama, južnoj americi i aziji.
clinical trials of efficacy against rotavirus gastroenteritis were performed in europe, the united states, latin america, and asia.

ispitivanje je također pokazalo da je u dojenčadi cijepljene cjepivom rotateq zabilježen manji broj prijema u bolnicu ili posjeta ustanovama za hitnu medicinsku pomoć zbog gastroenteritisa uzrokovanog rotavirusom.
the study also showed that there were fewer hospital admissions or visits to emergency clinics for rotavirus gastroenteritis in babies vaccinated with rotateq.

kliničke studije provedene su u europi, latinskoj americi, africi i aziji kako bi se procijenila zaštitna djelotvornost cjepiva rotarix protiv bilo kojeg oblika i teškog rotavirusnog gastroenteritisa.
clinical studies have been conducted in europe, latin america, africa and asia to evaluate the protective efficacy of rotarix against any and severe rotavirus gastro-enteritis.

premda je istodobna primjena s opv-om malo smanjila imunološki odgovor na cjepivo protiv rotavirusa, trenutno nema dokaza da utječe na kliničku zaštitu od teškog gastroenteritisa uzrokovanog rotavirusom.
although concomitant administration of opv slightly reduced the immune response to rotavirus vaccine, there is currently no evidence that clinical protection against severe rotavirus gastroenteritis would be affected.

djelotvornost cjepiva (%) protiv rotavirusnog gastroenteritisa koji zahtijeva hospitalizaciju i/ili rehidracijsku terapiju u medicinskoj ustanovi [95% ci]
vaccine efficacy (%) against rotavirus gastro-enteritis requiring hospitalisation and/or rehydration therapy in a medical facility [95% ci]

iako istodobna primjena opv cjepiva može neznatno smanjiti imunološki odgovor na cjepivo protiv rotavirusa, klinička zaštita protiv teškog gastroenteritisa izazvanog rotavirusom je dokazano održana u kliničkom ispitivanju koje je uključivalo više od 4200 ispitanika koji su primali rotarix istodobno s opv-om.
although concomitant administration of opv may slightly reduce the immune response to rotavirus vaccine, clinical protection against severe rotavirus gastro-enteritis was shown to be maintained in a clinical trial involving more than 4200 subjects who received rotarix concomitantly with opv.

u 68 038 cijepljene dojenčadi (34 035 u skupini koja je primila cjepivo) zaštitna djelotvornost cjepiva mjerena je smanjenjem stope hospitalizacija i posjeta hitnoj službi zbog gastroenteritisa uzrokovanog rotavirusom u vremenu od 14 dana nakon primitka treće doze cjepiva.
in 68,038 vaccinated infants (34,035 in the vaccine group) protective efficacy was measured as a reduction in the rate of hospitalisations and emergency department visits for rv gastroenteritis from 14 days after the third dose.

bolesniku valja dati detaljne upute kako postupati u takvim situacijama te upozoriti da u slučaju akutnog pogoršanja odmah potraži liječničku pomoć; osobito u slučaju gastroenteritisa, povraćanja i/ili proljeva što uzrokuje gubitak tekućine i soli, a također i neodgovarajuću apsorpciju peroralnog hidrokortizona.
the patient must be carefully informed how to act in these situations and also advised to immediately seek medical attention should an acute deterioration occur; especially in cases of gastroenteritis, vomiting and/or diarrhoea leading to fluid and salt loss, as well as to inadequate absorption of oral hydrocortisone.